A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.

Trial Profile

A Phase Ib, Open-label, Multi-center, Dose-escalation Study of Oral BKM120 in Combination With Oral GSK1120212 in Adult Patients With Selected Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2014

At a glance

  • Drugs Buparlisib (Primary) ; Trametinib (Primary)
  • Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Pharmacogenomic
  • Sponsors Novartis
  • Most Recent Events

    • 17 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Nov 2014 Planned End Date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
    • 12 Nov 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top